Get the Stockscreener App
3.185
0.47%
-0.015
MyMD Pharmaceuticals Inc stock is currently priced at $3.185, with a 24-hour trading volume of 16,820.
It has seen a -0.47% decreased in the last 24 hours and a +43.47% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.20 pivot point. If it approaches the $3.04 support level, significant changes may occur.
Previous Close:
$3.20
Open:
$3.27
24h Volume:
16,820
Market Cap:
$6.91M
Revenue:
-
Net Income/Loss:
$-5.38M
P/E Ratio:
-9.6515
EPS:
-0.33
Net Cash Flow:
$-13.30M
1W Performance:
+13.35%
1M Performance:
+43.47%
6M Performance:
+706.33%
1Y Performance:
+75.97%
1D Range:
$3.1014
$3.27
52W Range:
$0.108
$3.8412
MyMD Pharmaceuticals Inc Stock (MYMD) Company Profile
Name
MyMD Pharmaceuticals Inc
Sector
Industry
Phone
856 848 8698
Address
855 North Wolfe Street, Suite 601, Baltimore
MyMD Pharmaceuticals Inc Stock (MYMD) Latest News
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
Benzinga
Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket
Benzinga
Why LumiraDx Shares Are Trading Lower By 20%; Here Are 20 Stocks Moving Premarket
Benzinga
Why DouYu International Shares Are Trading Higher By 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why Bridgeline Digital Shares Are Trading Lower By 13%; Here Are 20 Stocks Moving Premarket
Benzinga
MyMD Pharmaceuticals Inc Stock (MYMD) Financials Data
MyMD Pharmaceuticals Inc (MYMD) Net Income 2024
MYMD net income (TTM) was -$5.38 million for the quarter ending September 30, 2023, a +63.37% increase year-over-year.
MyMD Pharmaceuticals Inc (MYMD) Cash Flow 2024
MYMD recorded a free cash flow (TTM) of -$13.30 million for the quarter ending September 30, 2023, a +10.37% increase year-over-year.
MyMD Pharmaceuticals Inc (MYMD) Earnings per Share 2024
MYMD earnings per share (TTM) was -$5.40 for the quarter ending September 30, 2023, a +50.00% growth year-over-year.
MyMD Pharmaceuticals Inc Stock (MYMD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Rivard Paul | Chief Legal Officer |
Aug 17 '23 |
Buy |
1.12 |
25,000 |
28,080 |
250,000 |
About MyMD Pharmaceuticals Inc
MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the causes of disease. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines; and to delay aging and increase longevity, as well as treat autoimmune diseases and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic derivative of cannabidiol for treating chronic pain, addiction, and epilepsy. The company was founded in 2014 and is headquartered in Baltimore, Maryland.
1.90%
3.27%
Cap:
|
Volume (24h):